Two-dimensional electrophoresis of prostate-specific antigen in sera of men with prostate cancer or benign prostate hyperplasia

Charrier, Jean-Philippe; Tournel, Carole; Michel, Sandrine; Dalbon, Pascal; Jolivet, Michel

doi:10.1002/(sici)1522-2683(19990101)20:4/5<1075::aid-elps1075>3.0.co;2-k

Cited by 47 publications

(31 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An increase or decrease in the content of this monosaccharide on a PSA N-glycan chain can modify the PSA's isoelectric point (pI). Two-dimensional gel electrophoresis has been used to evaluate sialic acid variations in PSA from different sources (Charrier et al, 1999;Isono et al, 2002;Jung et al, 2004;Tabares et al, 2007). Most of these studies have focused on fPSA 2-DE subforms, which represent only 10-30% of the total serum PSA.…”

supporting

confidence: 64%

Glycan Characterization of PSA 2-DE Subforms from Serum and Seminal Plasma

Sarrats

Saldova²,

Comet³

et al. 2010

OMICS: A Journal of Integrative Biology

View full text Add to dashboard Cite

Prostate-specific antigen (PSA) two-dimensional electrophoresis (2-DE) subforms (F1-F5) have been described to be altered in prostate cancer (PCa) compared to benign prostatic hyperplasia (BPH). To understand their molecular differences, characterization of these subforms from PCa serum and seminal plasma, namely, at the glycan level, was performed. PSA 2-DE subforms from two serum PCa samples and seminal plasma were analyzed by N-glycan sequencing using high-performance liquid chromatography (HPLC) combined with exoglycosidase array digestions and by mass spectrometry. F1, F2, and F3 subforms showed the same N-glycan pattern, which contained higher levels of sialic acid than the F4 subform, whereas the F5 subform was unglycosylated. When comparing PSA subforms from PCa with seminal plasma, a decrease in sialylation was observed. Furthermore, the analysis of F3, the more abundant PSA subform, showed a higher proportion of alpha 2-3 sialic acid and a decrease in core fucosylated glycans in the PCa sample. These N-glycan changes in PCa PSA subforms highlight the importance of glycosylation as an indicator of PCa disease.

show abstract

supporting

confidence: 64%

Glycan Characterization of PSA 2-DE Subforms from Serum and Seminal Plasma

Sarrats

Saldova²,

Comet³

et al. 2010

OMICS: A Journal of Integrative Biology

View full text Add to dashboard Cite

show abstract

“…However, many malignant cases still elude early detection and patients often present with metastasis at time of diagnosis (7,8) especially in the less developed world. Patients with occult metastases usually do not benefit from radical prostatectomy or radiotherapy and often respond less favorably to hormonal treatment (5,9).…”

Section: Introductionmentioning

confidence: 96%

Proteomics-based signature for human benign prostate hyperplasia and prostate adenocarcinoma

Alaiya

2011

Int J Oncol

View full text Add to dashboard Cite

Abstract. Prostate adenocarcinoma often presents at a late stage, due to a lack of early clinical symptoms and lack of accurate objective markers. This study aimed to identify and validate proteomics-based biomarkers useful for prostate cancer diagnosis and to establish a marker-panel for prostate cancer and benign prostate hyperplasia (BPH). Global protein expression patterns in fresh tissue specimens from 8 patients with prostate carcinoma and 16 with BPH were analyzed by two-dimensional gel electrophoresis. Differentially expressed proteins were identified by MALDI-TOF mass spectrometry. We compared our results with those of published studies and defined a set of common biomarkers. We identified 22 differentially expressed proteins between BPH and prostate carcinomas. The up-regulated proteins in cancer compared to BPH included protein disulfide-isomerase, 14-3-3-protein, Enoyl CoA-hydrase, prohibitin and B-tubulin β-2. Keratin-II, desmin, HSP71, ATP-synthase-β-chain and creatine kinase-β-chain were down-regulated. Survey of the literature showed that 15 of our 22 identified proteins have been previously reported to differ in their expression levels between BPH and prostate cancer by other laboratories. The expression patterns of these biomarkers could successfully cluster BPH and adenocarcinomas as well as prostate cancer of low and high Gleason scores. This study validates protein-biomarkers that can be useful for accurate diagnosis and prognostic monitoring of prostate adenocarcinoma. Despite varied prevalence of the disease between different ethnic populations (i.e., high in Sweden, low in Saudi Arabia); the biomarkers indicate that BPH and prostate cancers are biologically 'homogeneous' in their protein expression patterns across wide geographical regions. IntroductionProstate cancer accounts for approximately 25% of all newly diagnosed cancers and is the second leading cause of cancer deaths among the male population in America (1,2). While the prevalence of prostate cancer is relatively low in Saudi Arabia, it is the most commonly diagnosed cancer in men in Sweden (3). Even though the molecular variations in prostate carcinomas across wide geographical regions have not been extensively studied, the disease is relatively more common among AfroAmericans and often present with advanced stage disease compared to what is observed in American white men (4,5).An improvement and widespread availability in the measurement of PSA, such as PSA density, PSA volume and adjusted age-specific PSA ranges has resulted in early disease diagnosis in the Western world (6). However, many malignant cases still elude early detection and patients often present with metastasis at time of diagnosis (7,8) especially in the less developed world. Patients with occult metastases usually do not benefit from radical prostatectomy or radiotherapy and often respond less favorably to hormonal treatment (5,9). Prostate cancer is biologically heterogeneous with unpredictable aggressive behavior and currently the molecular events underlyin...

show abstract

“…The exact reason for this phenomenon has not been elucidated, but it has been shown that the fPSA fraction is heterogeneous (11,12 ). The so-called fPSA subforms proPSA, BPH-associated PSA, and intact PSA have been characterized in detail and recommended for diagnostic purposes (13)(14)(15)(16)(17)(18)(19)(20).…”

mentioning

confidence: 99%

“…The so-called fPSA subforms proPSA, BPH-associated PSA, and intact PSA have been characterized in detail and recommended for diagnostic purposes (13)(14)(15)(16)(17)(18)(19)(20). However, an even larger number of PSA subforms could be separated as specific spots by two-dimensional electrophoresis (2DE) and immunoblotting (11,21 ). Charrier and coworkers (11,22 ) used the 2DE pattern of fPSA subforms obtained by this technique as a tool to differentiate between patients with PCa and BPH.…”

mentioning

confidence: 99%

Analysis of Subforms of Free Prostate-Specific Antigen in Serum by Two-Dimensional Gel Electrophoresis: Potential to Improve Diagnosis of Prostate Cancer

Jung

Reiche²,

Boehme³

et al. 2004

Clinical Chemistry

View full text Add to dashboard Cite

Background:The aim of this study was to develop a method to separate and quantify subforms of free prostate-specific antigen (fPSA) in serum by two-dimensional electrophoresis and to assess the diagnostic accuracy of these subforms for prostate cancer (PCa) diagnosis in comparison with total PSA (tPSA) and the ratio of fPSA to tPSA (%fPSA). Methods: Sera from 50 patients with and without PCa, respectively, were studied. PSA was isolated by immunoadsorption on streptavidin-coated magnetic beads with biotinylated anti-PSA antibodies and separated by two-dimensional electrophoresis. After semidry blotting, the intensities of the fPSA spots were quantified by chemiluminescence using an imager analyzer. Results: The method detected subforms to a concentration of 0.1 g/L fPSA with an imprecision (CV) <16%. We detected 15 immunoreactive fPSA spots of different intensities. Spots F2 and F3 were present in all samples. F2 was lower in samples from non-PCa patients (median, 23%) than in samples from PCa patients (49%), whereas F3 behaved inversely (non-PCa, 73%; PCa, 45%). Ratios of F2 to F3 and F2/F3 to %fPSA, respectively, showed improved diagnostic accuracy compared with tPSA and %fPSA. Better differentiation by F2/F3 or

show abstract

Two-dimensional electrophoresis of prostate-specific antigen in sera of men with prostate cancer or benign prostate hyperplasia

Cited by 47 publications

References 35 publications

Glycan Characterization of PSA 2-DE Subforms from Serum and Seminal Plasma

Glycan Characterization of PSA 2-DE Subforms from Serum and Seminal Plasma

Proteomics-based signature for human benign prostate hyperplasia and prostate adenocarcinoma

Analysis of Subforms of Free Prostate-Specific Antigen in Serum by Two-Dimensional Gel Electrophoresis: Potential to Improve Diagnosis of Prostate Cancer

Contact Info

Product

Resources

About